Novel therapy for children with chronic hormone deficiency provides lifeline for parents

Apr 12, 2019

  • Alkindi® is the first replacement therapy specially designed for infants, children and adolescents with paediatric adrenal insufficiency
  • Adrenal insufficiency is caused by a lack of the stress hormone cortisol – which can be fatal
  • This new therapy, which has been developed by University of Sheffield spin-out company Diurnal, has been granted market authorisation by the European Medicine Agency.

Read more

Recent Blog Posts

What you should know about COVID-19 – updated 4th February

What you should know about COVID-19 – updated 4th February

Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 4th Feburary 2021 The Addison's Disease Self-Help Group has published guidance in conjuction with a...

Call out for young women with CAH!

Call out for young women with CAH!

DSD Families are recruiting young adults aged 16-25 with experience of variations of sex development to help shape and develop some of their peer psychosocial support ideas. Since CAH falls under the variations of sex development umbrella, they would like to speak to...

Society for Endocrinology statement on COVID-19 vaccines

Society for Endocrinology statement on COVID-19 vaccines

The Society for Endocrinology has released a statement on COVID-19 vaccines for patients with endocrine conditions - which states: "We are not aware of any specific side effects of a COVID-19 vaccine that would be unique to people with endocrine conditions" and that...